Objective: To assess the effect of continuous subcutaneous infusion of foslevodopa/foscarbidopa (LDP/CDP) on sleep in a patient with Parkinson’s disease (PD).

Background: Continuous subcutaneous infusion of LDP/CDP is a recently approved treatment for the treatment of PD patients with motor complications. This treatment may improve nocturnal motor symptoms and sleep status through continuous 24-hour administration; however, the effect on sleep is still unclear.

Method: Three patients who received continuous subcutaneous infusion of LDP/CDP at our hospital were evaluated before and after treatment using the off-time MDS-UPDRS, Beck’s Depression Questionnaire (BDI-II), autonomic symptoms (SCOPA-AUT), Epworth Sleepiness Scale (ESS), PD Sleep Scale (PDSS-2), and portable sleep EEG (EEG sensor ZA-X, Proassist). Sleep stages and sleep efficiency were evaluated using a portable sleep EEG (EEG sensor ZA-X, Proassist).

Results: Our three patients with PD were admitted for introduction of continuous subcutaneous infusion of LDP/CDP. They underwent a comprehensive evaluation including motor symptoms, autonomic symptoms, and sleep architecture before and after treatment initiation. Two weeks later, motor symptoms on off-state were improved and the off-time was reduced in all patients. Analysis of a portable sleep testing showed an increase in total sleep time, the percentage of stage N2 and stage N3. Also, the PD Sleep Scale-2 and Scales for Outcomes in Parkinson’s Disease – Autonomic Dysfunction (SCOPA-AUT) improved after LDP/CDP treatment.

Conclusion: Continuous subcutaneous infusion of LDP/CDP may be an effective treatment for improving sleep architecture.

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-effect-of-continuous-subcutaneous-foslevodopa-foscarbidopa-infusion-on-sleep-in-parkinsons-disease-three-case-reports/